BridgeBio: PDUFA Date Expected In November 2024 Could Shift Momentum

gorodenkoff/iStock via Getty Images The last time I spoke about BridgeBio Pharma, Inc. (NASDAQ:BBIO), it was in a Seeking Alpha article entitled "BridgeBio Pharma: FDA Submission Acromidis and Top-Line Results On Deck." The main thing to note about this article is that I mentioned that the New Drug Application [NDA] of this drug for the treatment of patients with transthyretin amyloid cardiomyopathy [ATTR-CM] was submitted to the FDA. However, at the time, there was to be a review period whereby the age ...